Fragrance for improving relaxation state and method of assessing
AssigneeGivaudan SA
InventorsGiuliano GAETA, Alan Forbes PROVAN, Natalie Anuradha T.D. GUNASEKARA, Ioannis KONTARIS
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of assessing the ability of a test fragrance ingredient or a test fragrance composition to improve the relaxation state of a human subject and of creating fragrance compositions having a relaxing effect on a human subject. It further relates to fragrance compositions for improving the relaxation state of a human subject, to consumer products comprising such fragrance compositions, and to methods of improving the relaxation state of a human subject.
Claims15
A method of assessing the ability of a test fragrance ingredient or a test fragrance composition to improve the relaxation state of a human subject, comprising the steps of:
- a) measuring a base relaxation state of one or more human test subject(s);
- b) providing the test fragrance ingredient or the test fragrance composition to the human test subject(s) for smelling;
- c) measuring a resulting relaxation state of the human test subject(s);
- and
- d) determining a difference between the resulting relaxation state and the base relaxation state for the human test subject(s);
- wherein the base relaxation state and the resulting relaxation state are measured by functional Near Infrared Spectroscopy (fNIRS) of the human test subject(s)' left brain hemisphere, right brain hemisphere, and full brain;
- wherein the test fragrance ingredient or the test fragrance composition is able to improve the relaxation state of the human subject if at least three out of the following six conditions are met:
- Condition 1:
- Deoxy Hb for the right brain hemisphere shows a statistically significant increase after 5-10 seconds of smelling;
- Condition 2:
- Oxy Hb for the full brain shows a statistically significant decrease after 30 seconds of smelling;
- Condition 3:
- Oxy Hb for the right brain hemisphere shows a statistically significant decrease after 0-10 seconds of smelling;
- Condition 4:
- Oxy Hb for the right brain hemisphere shows a statistically significant decrease after 0-5 seconds of smelling;
- Condition 5:
- Oxy Hb for the full brain shows a statistically significant decrease after 0-5 seconds of smelling;
- Condition 6:
- Oxy Hb for the right brain hemisphere shows a statistically significant decrease after 30 seconds of smelling;
- wherein Deoxy Hb is the amount of deoxygenated haemoglobin measured and Oxy Hb is the amount of oxygenated haemoglobin measured.
A fragrance composition for improving the relaxation state of a human subject, the fragrance composition comprising:
- a) at least about 25% by weight in total of at least five relaxing fragrance materials R;
- b) optionally up to about 45% by weight in total of non-relaxing fragrance materials NR, provided that the weight ratio of R to NR is at least 0.75;
- c) optionally up to about 75% by weight in total of neutral fragrance materials N;
- and
- d) optionally up to about 25% by weight in total of other fragrance materials M, provided that the weight ratio of R to (M+NR) is at least 0.75;
- wherein
- (i) all percentages are based on total weight of the fragrance materials constituting the fragrance composition;
- (ii) the relaxing fragrance materials R are selected from the group consisting of a musk ingredient, a floral-orris ingredient, a sweet-vanilla ingredient, a sweet-heliotrope ingredient, a sweet-tonka ingredient, a woody-vetiver ingredient, 2-(phenoxy)ethyl 2-methylpropanoate (phenoxyethyl isobutyrate), 1-(2-naphtalenyl)-ethanone (oranger crystals), 2-(4-methylcyclohex-3-en-1-yl)propan-2-ol (terpineol), (E)-1-methoxy-4-(prop-1-en-1-yl)benzene (anethole) 2-ethyl-4(2′,2′,3′-trimethylcyclopent-3-enyl)but-enol (Bangalol or Radjanol), basil oil, (E)-3,7-dimethylnona-1,6-dien-3-ol (ethyl linalool), 2-(2′-methylpropyl)-4-hydroxy-4-methyltetrahydropyran (Florosa), (E)-3,7-dimethylocta-2,6-dien-1-ol (geraniol), methyl 2-aminobenzoate (methyl anthranilate), (E)-3-methyl-4-(2,6,6-trimethyl-1-cyclohex-2-enyl)but-3-en-2-one (alpha-iso-methyl ionone), mixtures of 2-methyl-1-phenylpropan-2-yl butanoate and (phenoxy)ethyl 2-methylpropanoate (Prunella), 5-heptyldihydrofuran-2(3H)-one (gamma undecalactone or peach pure), and mixtures thereof;
- (iii) the non-relaxing fragrance materials NR are selected from the group consisting of 2-methylundecanal (methyl nonyl aldehyde), prop-2-enyl 2-(3-methylbutoxy)acetate (allyl amyl glycolate), (Z)-1-((3aS,6R,7R,8aS)-6,8,8-trimethyloctahydro-3H-3a,7-methanoazulen-3-ylidene)propan-2-one (acetyl cedrene), 3a,6,6,9a-perhydrotetra-methylnaphtho [2,1-b] furan (Amberlyn Super), pentyl 2-hydroxybenzoate (amyl salicylate), armoise oil, benzyl 2-hydroxybenzoate (benzyl salicylate), bergamot oil, 4-tert-butyl-3-phenylpropanal (Bourgeonal), cedar leaf oil, 3,7-dimethyloct-6-en-1-ol (citronellol), (E)-1-(2,6,6-trimethyl-1-cyclohexenyl)but-2-en-1-one (beta damas-cene), 2-methyl-1-phenylpropan-2-yl acetate (dimethyl benzyl carbinyl acetate), ethyl 2,6,6-trimethylcyclohexadienecarboxylate (Ethyl Safranate), methyl 2,4-dihydroxy-3,6-dimethylbenzoate (Evernyl or Everniate), (E)-3,7-dimethylocta-2,6-dienenitrile (geranyl nitrile), 3-(1,3-benzodioxol-5-yl)-2-methylpropanal (Helional or Tropional), Z-hex-3-enol, hexyl 2-hydroxybenzoate (hexyl salicylate), lemon oil, 2,4-dimethyl-3-cyclohexene-1-carbaldehyde (Cyclal C or Tricyclal or Ligustral), 3-(4-(1,1-dimethylethyl)phenyl-2-methylpropanal (Lilial), 4-(4-hydroxy-4-methylpentyl) cyclohex-3-enecarbaldehyde (Lyral), 3-methyl-5-phenylpentanol (Mefrosol), orange oil, orange terpenes, tagetes oil, 3,7-dimethyloctan-1-ol (pelargol), and mixtures thereof,
- (iv) the neutral fragrance materials N are selected from the group consisting of benzyl acetate, cassis base, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal (cyclamen aldehyde), (5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-one (carvone), (E)-3-phenylprop-2-en-1-ol (cinnamic alcohol), 2-methoxy-4-propylphenol (dihydro-eugenol), 2,6-dimethyloct-7-en-2-ol (dihydromyrcenol), 4-allyl-2-methoxyphenol (eugenol), galbanum, 5-hexyloxolan-2-one (gamma decalactone), 7-hydroxy-3,7-dimethyloctanal (hydroxycitronellal), 1H-indole, (E)-2-methoxy-4-(prop-1-en-1-yl)phenol (isoeugenol), jasmin oil, 3-pentyltetrahydro-2H-4-pyranyl ethanoate (Jasmopyrane Forte), 3,7-dimethylocta-1,6-dien-3-ol (linalool), 3,7-dimethylocta-1,6-dien-3-yl acetate (linalyl acetate), methyl 3-oxo-2-pentylcyclopentaneacetate (methyl dihydrojasmonate), patchouli oil, 2-phenylethyl alcohol, 4-methyl-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran (rose oxide), rose oil, 5-(2,2,3-trimethyl-3-cyclopentyl-3-methylpentan-2-ol (Sandalore), 1-phenylethyl acetate (styrallyl acetate), ylang-ylang, and mixtures thereof, and
- (v) the other fragrance materials M comprises fragrance materials not included in the above, excluding odourless or low-odour solvents or diluents used as vehicles for fragrance materials.
A method of using a fragrance ingredient in improving the relaxation state of a human subject, wherein the fragrance ingredient is selected from the group consisting of 17-oxacycloheptadec-6-en-1-one (ambrettolide), (9Z)-cycloheptadec-9-en-1-one (Civettone), (E)-3-methyl-5-cyclotetradecen-1-one (Cosmone), 1-(1,1,2,3,3,6-hexamethyl-2H-inden-5-yl)ethanone (Fixolide), (12E)-1-oxacyclohexadec-12-en-2-one (Habanolide), [2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methylpropyl]propanoate (Helvetolide), octahydrohexamethyl naphthoxirene (Moxalone), (5E)-3-methylcyclopentadec-5-en-1-one (Muscenone), 3-methyl-1-cyclopentadecanone (Muscone), 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone (musk ketone), 1,7-dioxacycloheptadecan-8-one (musk R1), (10Z)-13-methyl-1-oxacyclopentadec-10-en-2-one (Nirvanolide), 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methylpropyl cyclopropanecarboxylate (Serenolide), (3′E)-2-((3′,5′-dimethylhex-3′-en-2′-yl)oxy)-2-methylpropyl cyclopropanecarboxylate (Sylkolide), 1,15-pentadecanolide (Thibetolide), (5Z)-cyclohexadec-5-en-1-one (Velvione), N-1-(2,6,6-trimethyl-1-cyclohex-2-enyl)pent-1-en-3-one (Isoraldeine), 4-(2,6,6-trimethyl-1-cyclohex-2-enyl)pentanal (Cetonal), (E)-1-(2,6,6-trimethylcyclohex-2-en-1-yl)hepta-1,6-dien-3-one (cetone V), 4-(2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-one (dihydro-ionone beta), 7,9-dimethylspiro[5.5]undecan-3-one (Dispirone), (E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one (ionone beta), (E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one (irisone alpha), (E)-4-(2,5,6,6-tetramethylcyclohex-2-en-1-yl)but-3-en-2-one (irone alpha), (E)-3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one (Isoraldeine cetone alpha), (Z)-3,4,5,6,6-pentamethylhept-3-en-2-one (Koavone), benzoin resinoids, 3-ethoxy-4-hydroxybenzaldehyde (ethyl vanillin), 4-formyl-2-methoxyphenyl 2-methylpropanoate (Isobutavan), 4-hydroxy-3-methoxybenzaldehyde (vanillin), 2-methoxy-4-methylphenol (creosol), 2-ethoxy-4-(methoxymethyl)phenol (methyl diantilis), 2-propoxy-4-(methoxymethyl)phenol (propyl diantilis), 1-(4-methoxyphenyl)ethanone (acetanisole), 1-phenylethanone (acetophenone), 4-methoxybenzaldehyde (aubepine para cresol), benzo[d][1,3]dioxole-5-carbaldehyde (heliotropine), 1-(p-tolyl)ethanone (methyl acetophenone), octahydro-2H-chromen-2-one (bicyclononalactone), dec-9-en-1-yl (E)-3-(2-hydroxyphenyl)acrylate (Scentaurus Tonkarose), tonka bean oil, resinoid, extract or balsam, tonka roasted absolutes, coumarin replacers (e.g. Coumarex DB), and mixtures thereof.
Dependencies are inferred from the claim text.